BNTC
Benitec Biopharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.28
+10.48%Oct 28, 2026, 12:00 UTC
Benitec Biopharma announced positive interim Phase 1b/2a clinical results for high-dose BB-301 and continued durable improvements for low-dose BB-301 in patients with OPMD, reporting that all treated patients across both doses were formal responders.
Source:Oct 5, 2026, 12:00 UTC
Benitec Biopharma received formal FDA feedback following a Type C meeting regarding an open-label, single-arm pivotal study for BB-301, with the FDA requesting additional available data including data from Benitec's OPMD Natural History Study.
Source:Sep 30, 2026, 20:14 UTC
Benitec Biopharma Inc. changed its certifying accountant to Ernst & Young LLP on September 29, 2026.
Sep 24, 2026, 20:42 UTC
Benitec Biopharma Inc. dismissed Baker Tilly US, LLP as its independent auditor and appointed Ernst & Young LLP, effective September 18, 2026.
Sep 14, 2026, 20:00 UTC
Benitec Biopharma released its full year 2026 financial results and provided an operational update, reporting approximately $180 million in cash as of June 30, 2026.
Source: